Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab

Treatment of HER2-Expressing Breast Cancer and Ovarian Cancer Cells With Alpha Particle-Emitting 227Th-Trastuzumab

(2011) Helen Heyerdahl et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Improved efficacy of α-particle-targeted radiation therapy

(2010) Diane E. Milenic et al.   CANCER

Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel

(2010) Guenther G. Steger et al.   WIENER KLINISCHE WOCHENSCHRIFT

Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximab

(2009) Jostein Dahle et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2009) Neil L. Spector et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of α-particle-emitting 211At-labeled trastuzumab

(2009) Abraham Boskovitz et al.   NUCLEAR MEDICINE AND BIOLOGY

Relative Biologic Effects of Low-Dose-Rate α-Emitting 227Th-Rituximab and β-Emitting 90Y-Tiuexetan-Ibritumomab Versus External Beam X-Radiation

(2008) Jostein Dahle et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS